首页> 外文期刊>Journal of Ophthalmic and Vision Research >Intravenous Immunoglobulin for Management of Non-paraneoplastic Autoimmune Retinopathy
【24h】

Intravenous Immunoglobulin for Management of Non-paraneoplastic Autoimmune Retinopathy

机译:静脉注射免疫球蛋白,用于非平原性自身免疫视网膜病变

获取原文
       

摘要

Purpose: To report a case of non-paraneoplastic autoimmune retinopathy (npAIR) treated with intravenous immunoglobulin (IVIG). Case report: A 12-year-old boy presented with progressive visual field loss, nyctalopia, and flashing for three months. He had suffered from common cold two weeks before the onset of these symptoms. On the basis of clinical history and paraclinical findings, he was diagnosed with npAIR, and IVIG without immunosuppressive therapy was started. During the one-year follow-up period after the first course of IVIG, flashing disappeared completely. Visual acuity remained 10/10, but nyctalopia did not improve. Multimodal imaging showed no disease progression. Conclusion: Although established retinal degenerative changes seem irreversible in npAIR, IVIG may be a suitable choice to control the disease progression.
机译:目的:报告用静脉内免疫球蛋白(IVIG)治疗的非寄生体自身免疫视网膜病变(NPAIR)的情况。案例报告:一名12岁男孩呈现出渐进视野损失,尼克洛匹基亚,闪烁三个月。他在这些症状发作前两周患有普通感冒。在临床历史和旁立板发现的基础上,他被诊断出患有NPAir,并且开始了没有免疫抑制治疗的IVIG。在第一阶段的IVIG后的一年后续期间,闪烁完全消失。视力仍然是10/10,但尼克洛匹罗缺乏没有改善。多峰成像显示出没有疾病进展。结论:尽管在NPAir中建立了视网膜退行性变化似乎是不可逆转的,但IVIG可能是控制疾病进展的合适选择。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号